Do-Si-Dos | Cannabis Strain Review & Effects
Also known as: Dosi, Dosidos
Girl Scout Cookies x Face Off OG
Do-Si-Dos is a hybrid-leaning indica strain (Girl Scout Cookies x Face Off OG) with THC levels of 19-28%. It features a Limonene-dominant terpene profile and is known for relaxation and euphoria. Best used during the evening.
THC
19-28%
CBD
0-0.1%
Best Time
Primary Effects
Flavor Notes
Sweet, Floral, Earthy, Lime
Aroma
Sweet and floral with earthy undertones and lime zest
Research Sources
29 peer-reviewed studies
Verified Via
PubMed / DOI
Evidence
Research-Backed
Updated
December 2025
What is Do-Si-Dos?
Do-Si-Dos is a hybrid-leaning indica strain (Girl Scout Cookies x Face Off OG) with THC levels of 19-28%. It features a Limonene-dominant terpene profile and is known for relaxation and euphoria. Best used during the evening.
About Do-Si-Dos Strain
Do-Si-Dos is a potent indica-leaning Cookie cross known for its floral aroma and stoney relaxation. The limonene-linalool combination creates a unique profile offering mood elevation with deep calm—potentially ideal for stress and anxiety relief. Its Face Off OG parentage adds knockout sedation to the Cookie genetics.
Related Reading
Terpene Profile
Primary research: Calming & Relaxation
Primary research: Anti-inflammatory
Concentration Levels
Cannabinoid Profile
Therapeutic Profile Matches
Based on Do-Si-Dos's terpene and cannabinoid profile, it may be well-suited for these therapeutic applications:
migraines
- High linalool content supports migraines & headaches
- thc dominant ratio matches profile
- Best used evening, aligning with condition needs
anxiety
- High limonene content supports anxiety
- High linalool content supports anxiety
- High beta-caryophyllene content supports anxiety
ptsd
- High linalool content supports ptsd & trauma
- High beta-caryophyllene content supports ptsd & trauma
- thc dominant ratio matches profile
epilepsy
- High linalool content supports epilepsy & seizures
- High beta-caryophyllene content supports epilepsy & seizures
- Best used evening, aligning with condition needs
muscle spasms
- High linalool content supports muscle spasms & spasticity
- High beta-caryophyllene content supports muscle spasms & spasticity
- Best used evening, aligning with condition needs
Match scores are theoretical
These scores are based on terpene/cannabinoid research and do not guarantee specific effects. Individual responses vary significantly. Always consult a healthcare provider.
- 1
Tagen M, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol Drug and Alcohol Dependence. 2024
Johns Hopkins study showing limonene specifically reduces THC-induced anxiety in humans.
- 2
Vieira AJ, et al. Limonene: Aroma of innovation in health and disease Chemico-Biological Interactions. 2018
Comprehensive review of limonene's anxiolytic and antidepressant effects.
- 3
Kiecolt-Glaser JK, et al. Olfactory influences on mood and autonomic, endocrine, and immune function Psychoneuroendocrinology. 2008
Lemon scent exposure improved mood and reduced norepinephrine.
- 4
Sun J. D-Limonene: safety and clinical applications Alternative Medicine Review. 2007
D-limonene showed gastroprotective effects and clinical safety.
- 5
Linck VM, et al. Effects of inhaled Linalool in anxiety, social interaction and aggressive behavior in mice Phytomedicine. 2010
Linalool reduced anxiety without motor impairment.
- 6
Harada H, et al. Linalool Odor-Induced Anxiolytic Effects in Mice Frontiers in Behavioral Neuroscience. 2018
Showed linalool acts via olfactory system and GABA-A receptors.
- 7
Koulivand PH, et al. Lavender and the nervous system: Clinical evidence Evidence-Based Complementary and Alternative Medicine. 2013
Review of linalool-rich lavender for anxiety and mood.
- 8
Linck VM, et al. Inhaled linalool-induced sedation in mice Phytomedicine. 2009
Linalool increased sleep time without affecting REM sleep.
- 9
Peana AT, et al. Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils Phytomedicine. 2002
Linalool reduced edema and inflammation in rat models.
- 10
Gertsch J, et al. β-Caryophyllene is a dietary cannabinoid Proceedings of the National Academy of Sciences. 2008
Landmark paper: BCP directly activates CB2 receptors.
- 11
Klauke AL, et al. The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain European Journal of Pain. 2014
Showed dual mechanism for neuropathic pain relief.
- 12
Bahi A, et al. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice Physiology & Behavior. 2014
BCP reduced anxiety via CB2 receptor activation.
- 13
Horvath B, et al. β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner Free Radical Biology and Medicine. 2012
BCP reduced inflammation markers and oxidative stress.
- 14
Tambe Y, et al. Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene Planta Medica. 1996
BCP protected gastric mucosa in ulcer models.
- 15
Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish Journal of the American Chemical Society. 1964. doi:10.1021/ja01062a046
Landmark paper first identifying and synthesizing THC.
- 16
Whiting PF, et al. Cannabinoids for medical use: A systematic review and meta-analysis JAMA. 2015
Comprehensive review finding moderate evidence for chronic pain.
- 17
Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Pain Physician. 2017
Systematic review of clinical trials for neuropathic pain.
- 18
Lutge EE, et al. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS Cochrane Database of Systematic Reviews. 2013
Systematic review of cannabis for HIV/AIDS symptoms including appetite.
- 19
Smith LA, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy Cochrane Database of Systematic Reviews. 2015
High-quality evidence for CINV efficacy.
- 20
Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep Frontiers in Molecular Neuroscience. 2020
Review of THC effects on sleep architecture.
- 21
Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis European Journal of Neurology. 2011
Phase III trial showing efficacy for MS spasticity.
- 22
Silvestro S, et al. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease Molecules. 2020
Comprehensive review of CBD's therapeutic applications and molecular targets.
- 23
Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial Lancet. 2018
Phase III trial leading to FDA approval of Epidiolex.
- 24
Devinsky O, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial Lancet Neurology. 2016
Open-label trial showing 36.5% reduction in seizures.
- 25
Shannon S, et al. Cannabidiol in anxiety and sleep: A large case series Permanente Journal. 2019
79.2% of patients reported reduced anxiety within first month.
- 26
Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients Neuropsychopharmacology. 2011
CBD reduced anxiety in simulated public speaking test.
- 27
Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation Bioorganic & Medicinal Chemistry. 2015
Review of CBD's anti-inflammatory mechanisms.
- 28
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series Permanente Journal. 2019
66.7% of patients reported improved sleep in this anxiety and sleep study.
- 29
Urits I, et al. Use of cannabidiol (CBD) for the treatment of chronic pain Best Practice & Research Clinical Anaesthesiology. 2020
Comprehensive review of CBD for chronic pain management.
Research Verification
All citations link directly to PubMed or the original source. You can verify any claim by clicking the reference link. Learn more about how we research.
Frequently Asked Questions
How strong is Do-Si-Dos?
Do-Si-Dos is quite potent, typically testing between 19-28% THC. Its indica-leaning effects can be intensely relaxing, so new users should start with small amounts.
What does Do-Si-Dos smell like?
Do-Si-Dos has a sweet, floral aroma with earthy notes and lime zest. The linalool content gives it a lavender-like quality, while limonene adds citrus brightness.
Quick Facts
- Type
- Hybrid (Indica-leaning)
- Genetics
- Girl Scout Cookies x Face Off OG
- Breeder
- Archive Seeds
- Best Time of Use
- Evening
- Availability
- common
- Grow Difficulty
- moderate
Dominant Terpene
Limonene
Citrus, lemon, orange
Want to try Do-Si-Dos? Get your medical marijuana card today.
Get Your CardRelated by Genetics
Educational Information
This content is for educational purposes only and is not medical advice. Consult a healthcare provider before using cannabis products.
Strain Variability
Profiles vary between batches, growers, and growing conditions. Always check lab test results for the specific product you're purchasing.
Beyond Indica/Sativa
Effects are better predicted by cannabinoid and terpene profiles than strain classification. Focus on the chemistry, not the label.
Understanding Therapeutic Profiles
Learn how terpenes and cannabinoids work together to create each strain's unique effects and therapeutic potential through the entourage effect.
Learn About Therapeutic Profiles